Last Price$19.1(7.5%)
Market Cap$14.6B
N/A
Industry median - 16.5%
5Y Historical average - (5.3%)
N/A
Industry median - 6.8%
5Y Historical average - 44.1%
(94.8%)
Industry median - (16.5%)
5Y Historical average - 116.6%
84.8%
Industry median - 9.2%
5Y Historical average - 52.0%
SMMT Growth Rating
SMMT Growth rating
5.7
SMMT Growth rating performance
SMMT Growth Metrics
Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
Competing with SMMT Growth
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Growth score | Revenue Growth
(5Y CAGR) | Revenue Growth
(YoY) | Revenue Growth
(FWD) | EPS Growth
(5Y CAGR) | EPS Growth
(YoY) | EPS Growth
(FWD) | FCF Growth
(5Y CAGR) | FCF Growth
(YoY) |
$14.6B | 5.7 | (100.0%) | N/A | N/A | (7.1%) | (94.8%) | 6.8% | 44.6% | 84.8% | |
$402.0B | 7.6 | 18.9% | 25.0% | 19.9% | 6.7% | (17.3%) | 23.5% | 14.5% | 0.0% | |
$125.5B | 6.8 | 21.5% | 11.5% | 6.8% | N/A | N/A | (988.1%) | N/A | N/A | |
$74.0B | 5.5 | 12.6% | 8.3% | 3.4% | 16.1% | 10.3% | 9.5% | 12.5% | (5.7%) | |
$38.1B | 6.2 | 106.9% | 127.3% | 76.7% | (9.7%) | (57.5%) | (141.9%) | N/A | (70.8%) | |
$31.3B | 5.4 | 59.2% | 23.0% | 16.9% | (23.2%) | (38.5%) | (55.3%) | (36.7%) | N/A | |
$27.1B | 6.1 | 83.9% | (54.1%) | (28.2%) | 29.6% | N/A | (182.9%) | N/A | (79.0%) | |
$15.2B | 4.9 | 4.5% | (3.8%) | 35.2% | (19.0%) | (9.0%) | 132.7% | 10.6% | 215.8% | |
$14.8B | 3.8 | 14.5% | 14.8% | 9.3% | (35.1%) | (91.0%) | 3,612.9% | (18.0%) | (47.6%) | |
$14.0B | 7.5 | 14.7% | 23.6% | 10.7% | N/A | 25.6% | 9.9% | N/A | 44.5% | |
$1,846.9M | 5.0 | 50.5% | 50.5% | 50.7% | (11.2%) | (16.6%) | (35.6%) | 2.7% | (45.5%) |
FAQ
What is the Summit Therapeutics Inc. (SMMT) revenue growth?
The Summit Therapeutics Inc. (SMMT) revenue growth is N/A, which is lower than the industry median of 16.5% and the 5-year historical average of (5.3%).
What is the Summit Therapeutics Inc. (SMMT) operating income growth?
The Summit Therapeutics Inc. (SMMT) operating income growth is N/A, compared to the industry median of 6.8% and the 5-year historical average of 44.1%.
What is the Summit Therapeutics Inc. (SMMT) EPS (Earnings Per Share) growth?
The Summit Therapeutics Inc. (SMMT) EPS growth is (94.8%), compared to the industry median of (16.5%) and the 5-year historical average of 116.6%.
What is the Summit Therapeutics Inc. (SMMT) Free Cash Flow (FCF) growth?
The Summit Therapeutics Inc. (SMMT) Free Cash Flow growth is 84.8%, compared to the industry median of 9.2% and the 5-year historical average of 52.0%.